Spirovant Sciences‘ lead gene therapy candidate for select cystic fibrosis (CF) patients, SPIRO-2101, was given rare pediatric disease and…
Articles by Forest Ray PhD
The airways of cystic fibrosis (CF) patients show unusual levels of an antibody called BPI-ANCA, and they correlate with…
Moderna Therapeutics and Vertex Pharmaceuticals have entered a three-year research and licensing agreement aimed at developing gene-editing delivery…
The U.S. Food and Drug Administration (FDA) has agreed to simplify Aridis Pharmaceuticals‘ planned Phase 2 trial of…
Savara Pharmaceuticals is stopping its Phase 2a exploratory clinical study of Molgradex (molgramostim nebulizer solution) to treat nontuberculous mycobacterial (NTM) lung infection in…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography…
People with cystic fibrosis (CF) in the U.K. have grown more numerous, older, and more diverse, according to the…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the…
Poorer oxygen uptake and transport may underlie skeletal muscle differences that affect exercise tolerance in children and adolescents with…
Enterprise Therapeutics announced that dosing has begun in a Phase 1 clinical trial testing ETD002, a potential inhaled treatment for …